Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2022-06-08 Audit Report / Informat…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Full Year Results
Audit Report / Information Classification · 95% confidence The document is a comprehensive 'Full Year Results' report for Evgen Pharma plc for the year ended 31 March 2022. It includes a Chairman's Statement, a Chief Executive's Report, operational highlights, and financial highlights. While it begins with an RNS header, the document length (over 49,000 characters) and the inclusion of detailed strategic and management reports indicate this is the full annual financial report rather than a mere announcement of the report's publication. FY 2022
2022-06-08 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) titled 'Notice of Results' issued by Evgen Pharma plc. It informs the market that the company will be announcing its audited results for the year ended 31 March 2022 on the following day. Per the 'Menu vs Meal' rule, this is an announcement regarding the publication of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2022-06-07 English
Collaboration with Università Sapienza di Roma
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service, which is explicitly identified as a non-regulatory news service. It announces a research collaboration between Evgen Pharma plc and Università Sapienza di Roma. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and is a general corporate announcement distributed via RNS/Reach, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous corporate announcements.
2022-05-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' for Evgen Pharma PLC. It explicitly details a change in voting rights held by a shareholder (James Robert Kight), crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2022-04-29 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for Evgen Pharma PLC. It is a technical market announcement regarding trading volatility and auction extensions, not a financial report, management update, or corporate filing. As it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2022-03-15 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for Evgen Pharma PLC. It is a standard market operational notice rather than a financial report, management update, or corporate filing. As it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2022-03-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.